TABLE 1.

Demographics of individuals included in this study

Demographics	HC	PSP‐RS	AD continuum	PSP‐non‐RS	P values
n (race: all Asian)	50	46	37	11
Age (y)	64.0 ± 11.5	71.4 ± 7.5**	69.1 ± 11.0	71.7 ± 6.2	0.005
Male sex, n (%)	29 (58)	28 (61)	15 (41)	6 (55)	0.27
Amyloid‐β positive	0	0	37	0
Disease duration (y)		3.4 ± 2.5	2.7 ± 2.2	3.3 ± 2.0	0.2
UPDRS Part III score	1.4 ± 2.4 (n = 40)	34.2 ± 14.5****,#### (n = 43)	2.2 ± 4.4 (n = 29)	21.5 ± 9.0***,##	<0.0001
PSP rating scale	1.8 ± 2.0 (n = 20)	40.0 ± 17.4****,##	4.7 ± 1.0 (n = 6)	20.6 ± 9.2*	<0.0001
MMSE	29.3 ± 0.9	23.8 ± 6.5**** (n = 43)	21.6 ± 3.5**** (n = 36)	26.4 ± 3.2*,#	<0.0001
MoCA	27.4 ± 2.1 (n = 15)	22.6 ± 3.9 (n = 5)	15.3 ± 4.7**** (n = 7)	26 a (n = 1)	<0.0001
FAB	16.4 ± 1.3 (n = 48)	11.6 ± 3.8**** (n = 40)	12.5 ± 3.4**** (n = 32)	12.6 ± 3.2***	<0.0001
GDS	1.6 ± 1.2 (n = 32)	6.4 ± 4.1**** (n = 39)	4.3 ± 2.8*** (n = 34)	5.5 ± 2.0****	<0.0001
Apathy	9.5 ± 5.4 (n = 38)	17.9 ± 8.9**** (n = 38)	14.7 ± 7.4** (n = 35)	17.6 ± 6.7*	<0.0001
CDR	NE	0.7 ± 0.7# (n = 14)	0.9 ± 0.5 (n = 36)	0.5 ± 0.3# (n = 9)	0.004
CDR‐SoB	NE	4.7 ± 4.6 (n = 14)	4.1 ± 2.8 (n = 36)	1.8 ± 1.4# (n = 9)	0.04

****P < 0.0001, ***P <0.001, **P <0.01, *P < 0.05 versus HC post hoc Dunn's test; ^#### P < 0.0001, ^### P < 0.001, ^## P < 0.01, ^# P < 0.05 versus AD continuum post hoc Dunn's test.

^a Statistics not examined.

HC, healthy control; PSP‐RS, progressive supranuclear palsy–Richardson's syndrome; AD, Alzheimer's disease; PSP‐non‐RS, progressive supranuclear palsy without Richardson's syndrome; UPDRS III, Unified Parkinson's Disease Rating Scale Part III; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; FAB, Frontal Assessment Battery; GDS, Geriatric Depression Scale; CDR, Clinical Dementia Rating scale; NE, not examined; CDR‐SoB, Clinical Dementia Rating scale Sum of Boxes.